BIOMAP's aim is to improve the lives of patients affected by the two most common inflammatory skin conditions: Atopic Dermatitis and Psoriasis. Addressing key unmet needs in the treatment of the diseases by analysing data from more than 50,000 patients, the five-year project will have a broad impact on disease understanding, patient care, and future therapies. The team is comprised of 26 academic and five industry partners as well as five patient organisations.

This is the first IMI project in the field of dermatology and is funded jointly by the Innovative Medicines Initiative, the European Commission and the participating pharmaceutical companies. (Please find the full press release under BIOMAP project’s website: here).

The Department of Innovation and Digitalisation is excited to support the BIOMAP project on legal and ethical issues.